QEII Health Sciences Centre

Running trials

• Not yet recruiting

  A Mindfulness-based Stress Reduction Program for IBD

  NCT07266883· Source

• Not yet recruiting

  Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)

  NCT07831122· Phase 1· Source

• Active, not recruiting

  A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

  NCT07036523· Phase 2· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Source

• Active, not recruiting

  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  NCT06413498· Phase 3· Source

• Active, not recruiting

  A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

  NCT05963074· Phase 2· Source

• Recruiting

  Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

  NCT05601440· Phase 2· Source

• Recruiting

  IBD Strong Peer2Peer for Self-Management of Psychological Distress

  NCT05722236· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Recruiting

  A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  NCT05623020· Phase 3· Source

• Recruiting

  Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

  NCT05180097· Phase 2· Source

• Active, not recruiting

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797· Phase 3· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382286· Phase 3· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382299· Phase 3· Source

• Recruiting

  Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

  NCT04685616· Phase 3· Source

• Enrolling by invitation

  The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors

  NCT05116137· Source

• Recruiting

  Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)

  NCT06844227· Source

• Recruiting

  Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

  NCT04895839· Source

• Recruiting

  RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

  NCT04796350· Source

• Active, not recruiting

  Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

  NCT04566887· Phase 2· Source

• Active, not recruiting

  Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer

  NCT03784755· Source

• Active, not recruiting

  Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

  NCT03715478· Phase 1/2· Source

• Active, not recruiting

  Prostate Cancer Biomarker Enrichment and Treatment Selection

  NCT03385655· Phase 2· Source

• Active, not recruiting

  Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

  NCT03410615· Phase 2· Source

• Active, not recruiting

  Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT02905318· Phase 2· Source

• Active, not recruiting

  Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

  NCT02436707· Phase 2· Source

• Active, not recruiting

  A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

  NCT01396408· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Crohn's disease2 recruiting
• Hodgkin lymphoma2 recruiting
• Multiple myeloma2 recruiting
• Ulcerative colitis2 recruiting
• Atrial fibrillation1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• Metastatic breast cancer1 recruiting
• Osteoporosis1 recruiting
• Prostate cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Source

• Withdrawn

  Improving Patient Outcomes Through the Implementation of an IBD Biologic Care Pathway

  NCT06030882· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Source

• Withdrawn

  90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients

  NCT05686135· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Source

• Completed

  Procedure for Duodenal-Ileal Diversion With a Sleeve Gastrectomy for Patients With Obesity and Type 2 Diabetes Mellitus

  NCT04627103· Source

• Completed

  Guideline-Directed Medical Therapy in Patients After Implantation of Implantable Cardioverter Defibrillators to Improve Long-Term Outcomes

  NCT04505007· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Source

• Completed

  A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  NCT03652064· Phase 3· Source

• Completed

  NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

  NCT03259035· Phase 2· Source

• Completed

  Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT03391466· Phase 3· Source

• Completed

  A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03277105· Phase 3· Source

• Completed

  Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

  NCT02879162· Phase 2· Source

• Completed

  Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

  NCT02630693· Phase 2· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Source

• Completed

  Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

  NCT01658930· Source